Department of Medical Economics, Institute of Social- and Preventive Medicine, University of Zurich, Zurich, Switzerland.
J Hum Hypertens. 2010 Feb;24(2):117-23. doi: 10.1038/jhh.2009.47. Epub 2009 Jun 18.
This analysis shows the economic benefit of antihypertensive treatment in patients 80 years of age or older from the perspective of the Swiss healthcare system. The cost-effectiveness analysis of antihypertensive treatment in the elderly was carried out applying the results of the Hypertension in the Very Elderly Trial study to the Swiss healthcare system. The analysis shows that hypertension treatment provides, compared with placebo, an additional life expectancy of 0.0457 years per patient, over a follow-up period of 2 years. The medication cost was covered by the reduction of costs related to the treatment of strokes, myocardial infarctions and heart failure: the total cost per patient in the active group resulted in a dominant strategy of savings compared with the placebo group. Sensitivity analysis yielded a stable estimate after varying the costs of medication, stroke, myocardial infarction, heart failure and life expectancy, confirming the robustness of these results. Moreover, considering that antihypertensive treatment also positively affects the incidence of dementia, those net benefits might even be underestimated.
这项分析从瑞士医疗保健系统的角度展示了 80 岁及以上老年患者接受降压治疗的经济效益。对老年人群降压治疗的成本效益分析是将 Hypertension in the Very Elderly Trial 研究的结果应用于瑞士医疗保健系统进行的。分析表明，与安慰剂相比，高血压治疗为每位患者提供了额外的 0.0457 年的预期寿命，随访期为 2 年。药物治疗的费用通过降低与中风、心肌梗死和心力衰竭相关的治疗费用来覆盖：在活跃组中，每位患者的总成本相对于安慰剂组呈现出主导策略的节约。在改变药物治疗、中风、心肌梗死、心力衰竭和预期寿命的成本后，敏感性分析得出了稳定的估计值，这证实了这些结果的稳健性。此外，考虑到降压治疗也会积极影响痴呆症的发病率，这些净收益甚至可能被低估。
